Efficacy Evaluation of Recombinant Human Growth Hormone in Children with Advanced Bone Age

Objective: To explore the treatment effect of recombinant human growth hormone in children advanced bone age, and to provide evidence for its clinical application. Methods: A total of 25 children with advanced bone age who visited the Children's Hospital in Hebei Province from 2021 to 2024 were selected. Among them, there were 8 cases of idiopathic short stature (ISS) and 7 cases of growth retardation. There were 15 males and 10 females. All patients received recombinant human growth hormone treatment at a dose of 0.17 - 0.18 U/kg.d. The treatment duration was determined based on the treatment effect, economic condition, tolerance to injections, and satisfaction with height, ranging from 3 months to 14 months. The changes before and after treatment were observed, and the efficacy was evaluated. The effective rate was 96%. The changes in blood routine, thyroid function, liver and kidney functions, glucose metabolism indicators (fasting blood glucose, fasting insulin, glycated hemoglobin), IGF-1, and BP3 were monitored. Results: The height was significantly improved compared with that before treatment. Before treatment, the patients' height was at -1.63 ± 0.66SD, and after treatment, the final height was at -1.18±0.67SD, with a statistically significant difference. The height growth rate in the first three months of treatment was significantly faster than the growth rate from 3 to 6 months, with a statistically significant difference. There was no significant difference in the treatment effect between males and females at 3 and 6 months. After 3 months of treatment, the FT4 indicator was significantly lower than before treatment, with a statistically significant difference. There was an upward trend in insulin and blood glucose after treatment, but without a statistically significant difference. There was no significant change in glycated hemoglobin before and after treatment. IGF-1 was significantly higher at 6 months and 3 months after treatment than before treatment, and was higher at 6 months than at 3 months, all with statistically significant differences. BP-3 increased at 3 months compared to before treatment, and at 6 months compared to 3 months, but the difference was not statistically significant. However, it was significantly higher at 6 months compared to before treatment, with a statistically significant difference. Total bile acids were significantly higher at 6 months compared to before treatment and at 3 months, with a statistically significant difference. White blood cells were significantly higher at 3 months compared to before treatment, with a statistically significant difference. Conclusion: Recombinant human growth hormone is effective in treating children with advanced bone age, with significant growth in the first three months of treatment.